Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Showing posts with label circle of Willis. Show all posts
Showing posts with label circle of Willis. Show all posts

Friday, August 21, 2026

FDA confirms Class I recall for thousands of stroke prevention devices

 YOU better be prepared to quiz your doctor on this.

I'm missing the reasoning behind even using these. The obvious solution is check if the Circle of Willis is complete, then close up the offending artery! You would still have 3 arteries supplying blood to the brain.

FDA confirms Class I recall for thousands of stroke prevention devices

The U.S. Food and Drug Administration (FDA) has confirmed a new recall for Boston Scientific’s Enroute Transcarotid Neuroprotection System and Enroute Transcarotid Neuroprotection System Plus. The recall was put in place due to a risk of arterial sheath tip separation or partial tip separation during use. One serious injury has been linked to this issue.

The FDA first warned the public about these risks in July as part of its Early Alert pilot program. The issue was still under investigation at that time. Now, the agency has reached its conclusion that this is a Class I recall, which means these devices are associated with a risk of “serious adverse health consequences or death.”  

This recall includes more than 115,000 units of the Enroute Transcarotid Neuroprotection System and nearly 50,000 units of the Enroute Transcarotid Neuroprotection System Plus. Customers with any of these devices on hand should stop using them right away and start the process of returning them to Boston Scientific. If customers know of any Enroute systems forwarded from one facility to the next, they should communicate with that facility about this concern.

Click here for more information from the FDA, including specific lot numbers.

Additional details about these devices

The Enroute Transcarotid Neuroprotection System and Enroute Transcarotid Neuroprotection System Plus are used by vascular surgeons and interventional cardiologists to perform transcarotid artery revascularization procedures. The Enroute system delivers transcarotid vascular access to clinicians and reduces the risk of stroke for patients presenting with carotid artery disease. It reverses blood flow in a way that keeps embolic debris away from the brain, providing clinicians with a minimally invasive alternative to carotid endarterectomy.

Tuesday, June 16, 2026

New Data Presented at VAM26 Explores How Carotid Endarterectomy and Carotid Artery Stenting Compare in Real-World Patient Populations

 I can't ever see doing carotid stenting or endarterectomy with all the risks of those procedures. Your doctor NEEDS TO GUARANTEE NO PROBLEMS IF DONE OR THE MEDICAL LICENSE IS LOST! 

Here is why your doctor needs to GUARANTEE NO complications from stenting!

 The obvious solution is check if the Circle of Willis is complete, then close up the offending artery!

My right carotid artery was at 80% blockage at time of stroke and then thankfully fully closed up 3 years later. Remained closed for 10 years and I cognitively functioned quite well with no episodes of fainting or poor executive functioning. Eventually collaterals grew around the blockage. Since my Circle of Willis is complete, I still had 3 fully functioning arteries supplying blood to the brain, obviously enough to keep me highly functioning. I'm glad that my doctors were so incompetent they never found that 80% blockage, otherwise they probably would have insisted I undergo either stenting or endarterectomy, both of which they couldn't guarantee no problems. And I didn't find out about those problems until years later researching for this blog.

The latest here:

New Data Presented at VAM26 Explores How Carotid Endarterectomy and Carotid Artery Stenting Compare in Real-World Patient Populations

Study Finds Long-Term Stroke and Death Rates Favor Carotid Endarterectomy (CEA) over Carotid Artery Stenting (CAS) in Treating Patients with Asymptomatic Carotid Artery Stenosis 

BOSTON, MA, JUNE 13, 2026 – Today, the Society for Vascular Surgery (SVS) announced the findings of a new study demonstrating the safety and efficacy of emerging treatment options for patients with asymptomatic carotid stenosis (ACS).

Carotid stenosis occurs when plaque builds up in the carotid artery, narrowing the vessel and restricting blood flow to the brain and can lead to stroke. However, ACS occurs when the artery is narrowed by at least 70-80% without a recent stroke, significantly increasing the risk of future stroke, cardiovascular events, and cognitive decline. It is estimated that two million North Americans and Europeans live with treatable asymptomatic carotid artery stenosis (NIH).

In November 2025, the New England Journal of Medicine published data from the Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Study (CREST-2), focused on revascularization practices to manage stroke risk in ACS patients. SVS published an opinion piece on why CREST-2 trial results should inform, not replace, clinical judgement due to how the trial reflects idealized medical therapy, not routine clinical practice. 

“Data presented at the Society for Vascular Surgery’s Vascular Annual Meeting underscores the importance of knowledge of which intervention, if any, is optimal for stroke management in patients with carotid disease,” said Keith D. Calligaro, MD, Chief, Vascular Surgery at Pennsylvania Hospital, President, Society for Vascular Surgery. “We should not disregard the findings of many past studies showing the benefit of carotid endarterectomy over carotid stenting in selected patients. The findings highlight the need for randomized clinical trials, real-world outcomes data, and the expertise of vascular surgeons, the only specialty that can perform trans-femoral carotid stenting, TCAR and CEA.”

Carotid Stenosis Patients Experience Improved Stroke and Mortality Outcomes Three Years After CEA than CAS

Using the TriNetX Collaborative US Network, a multi-institutional electronic health record platform continuously updating real-world data from healthcare organizations, researchers aim to compare perioperative and long-term outcomes of CEA and CAS in asymptomatic patients. Researchers selected adult patients with ACS who underwent CEA or CAS from the TriNetX Network. Patients were matched 1:1 using a propensity score match (PSM) to balance baseline characteristics like demographics, comorbidities, and relevant medications. The study’s primary outcomes included stroke, death, and the composite outcome of stroke or death at 30 days, one year, three years, and five years.

The study identified 101,714 patients in total, 61,124 of whom underwent CEA (60.1%) and 40,590 CAS (39.9%). Through PSM, 39,471 patients were matched to each cohort with balanced baseline characteristics. The CEA group showed consistently lower rates of stroke at 30 days (2.0% vs 2.4%, p=0.001), one year (2.9% vs 3.3%, p=0.001), three years (3.6% vs 3.9%, p=0.008), and five years (4.1% vs 4.4%, p=0.038). This group also saw significantly lower mortality rates at three years (11.8% vs 12.4%, p=0.014),though other time points reflected similar rates. At every time period stroke or death outcomes favored the CEA group, with significant differences observed at 30 days (3.9% vs 4.2%, p=0.049), one year (8.7% vs 9.4%, p=0.001), three years (14.9% vs 15.8%, p< 0.001), and five years (20.1% vs 20.8%, p=0.013).

“Our results suggest that CEA has more favorable stroke and mortality outcomes when patient demographics are equal,” said lead author Anthony H. Chau, MD, Associate Professor of Vascular and Endovascular Surgery, University of California, Irvine. “However, our findings do not conclude that every patient should undergo CEA. Instead, they remind us how paramount patient selection is when treating carotid artery stenosis, and the detail that should go into selecting the right procedure for the right patient.”

Session Details:

  • “Carotid endarterectomy has improved long-term stroke and survival compared to carotid artery stenting in a real-world propensity-matched cohort analysis using the TriNetX Network”
    • Saturday, June 13th from 9:04 am – 9:11 am ET (Plenary 7)

### 

About the Society for Vascular Surgery
The Society for Vascular Surgery® (SVS) seeks to advance excellence and innovation in vascular health through education, advocacy, research, and public awareness. The organization was founded in 1946 and currently has a membership of approximately 6,500. SVS membership is recognized in the vascular community as a mark of professional achievement. For more information, visit Vascular.org.

About VAM26
The Society for Vascular Surgery’s Vascular Annual Meeting (VAM) will be held in Boston, MA, on June 10-13. Leading physicians, researchers, and health care professionals in vascular surgery gather for three full days of groundbreaking educational content showcasing the latest data, research, and innovations in vascular surgery and vascular health. For more information, visit vam.vascular.org.

Press Contact:

Bethany Grassley

bgrassley@brgcommunications.com

703-739-834

Monday, June 8, 2026

Non‑O blood type is linked to higher post‑CAS stroke and TIA risk

 I can't ever see doing carotid stenting or endarterectomy with all the risks of those procedures. Your doctor NEEDS TO GUARANTEE NO PROBLEMS IF DONE OR THE MEDICAL LICENSE IS LOST! 

Here is why your doctor needs to GUARANTEE NO complications from stenting!

 The obvious solution is check if the Circle of Willis is complete, then close up the offending artery!

My right carotid artery was at 80% blockage at time of stroke and then thankfully fully closed up 3 years later. Remained closed for 10 years and I cognitively functioned quite well with no episodes of fainting or poor executive functioning. Eventually collaterals grew around the blockage. Since my Circle of Willis is complete, I still had 3 fully functioning arteries supplying blood to the brain, obviously enough to keep me highly functioning. I'm glad that my doctors were so incompetent they never found that 80% blockage, otherwise they probably would have insisted I undergo either stenting or endarterectomy, both of which they couldn't guarantee no problems. And I didn't find out about those problems until years later researching for this blog.

The latest here:

Non‑O blood type is linked to higher post‑CAS stroke and TIA risk

BACKGROUND

Carotid angioplasty and stenting (CAS) has increasingly been used as an alternative to carotid endarterectomy (CEA) in the treatment of carotid artery disease. However, neurological complications following carotid angiography or CAS remain a clinical concern. This study aimed to evaluate whether naturally occurring ABO blood group antigens and hematological parameters are associated with cerebrovascular complications after diagnostic or therapeutic carotid angiography.

METHODS

In this single-center retrospective study, patients were classified as blood group O or non-O (A, B, or AB). Cerebrovascular complications were defined as in-hospital amaurosis fugax, transient ischemic attack (TIA), or stroke occurring after carotid angiography or carotid artery stenting (CAS).

RESULTS

A total of 316 patients who underwent carotid angiography were included; 106 (33.5%) had blood group O and 210 (66.5%) had non-O blood groups. Cerebrovascular events were significantly more frequent in patients with non-O blood groups. Stroke occurred in 13.8% of patients with non-O blood groups compared with 1.9% in those with blood group O (p < 0.001), while TIA was also more common in the non-O group (11.0% vs. 3.8%, p = 0.033). When stratified by procedure type, this association was predominantly observed in patients undergoing CAS, whereas cerebrovascular event rates were low and comparable between groups in patients undergoing diagnostic angiography alone. In univariable analysis, diabetes mellitus was associated with stroke (OR = 2.392, p = 0.024), while blood group O was associated with lower odds of stroke (OR = 0.120, p = 0.004). In multivariable analysis, blood group O (OR = 0.127, p = 0.007) and contrast volume (OR per 10 mL increase: 1.218, p < 0.001) remained independently associated with stroke, whereas diabetes mellitus was no longer statistically significant.

CONCLUSION

Non-O blood groups were associated with a higher risk of stroke and TIA following carotid angiography, particularly in patients undergoing CAS, whereas blood group O was associated with a lower risk of stroke. These findings should be interpreted with caution due to the observational design and potential residual confounding.

REFERENCES

  1. ABO blood group and cerebrovascular complications after carotid angiography and stenting: a natural thrombotic marker?

    Evsen A, Altunova M.

    J Clin Neurosci. 2026 Jun 7; 152 112128 [Epub ahead of print]

Friday, April 3, 2026

Managing Asymptomatic Carotid Stenosis in 2026

 

 I had zero risk factors for this and was totally asymptomatic, except that my Dad had 80% blockage and his doctor failed to tell him that any children had moved into the high risk category for carotid stenosis. So, my stroke was totally preventable except my dads' doctor failed at getting me informed of my risk.

My stroke doctors never diagnosed carotid stenosis in me even though 3 years later the right carotid artery completely closed up which my doctor at the time said it would have been 80% blocked at the time of my stroke, when it dissected. You can easily see the complete failure of my doctors at this! Very luckily, I didn't dissect that plaque again and suffer another stroke, no thanks to my doctors!

Managing Asymptomatic Carotid Stenosis in 2026

Dear colleagues, I am Christoph Diener, from the Faculty of Medicine at the University of Duisburg-Essen in Germany. My video this month concentrates on one important topic only, and this is the management of asymptomatic carotid stenosis. 

Defining Asymptomatic Carotid Stenosis

Asymptomatic stenosis of the internal carotid artery is defined as a stenosis of 50% or more,and these stenoses are usually found at the origin of the internal carotid artery. Asymptomatic carotid stenosis can lead to ischemic strokes caused by embolization from an ulcerated plaque, or very rarely, hemodynamically, if an occlusion of the internal carotid artery occurs.

How are these stenoses identified usually? During screening examinations that people who have coronary artery disease or peripheral arterial disease undergo, or when those older than 60 or 65 years see their internist for a yearly checkup. 

Suggested for you

The first studies comparing optimal drug therapy with carotid endarterectomy were conducted in the 1990s and the early 2000s, and these were the ACAS and ACST studies. At that time, the best possible medical treatment consisted of administrating aspirin and treating arterial hypertension

The annual risk for ipsilateral stroke, perioperative stroke, or death over 5 years in the ACAS study was 5% for patients who underwent endarterectomy and 11% for patients who received best medical treatment. This translated to a 53% risk reduction in favor of carotid surgery, and at that time, carotid surgery was recommended. 

Subsequently, a number of additional studies were done comparing surgical treatment with optimal medical therapy. These included between 450 and 3600 patients, and the absolute risk reduction in favor of surgery over best medical treatment was variable, ranging from, in an optimal case, 5.4% to only 3.3%, which was no longer statistically significant. 

In the next 10 years, seven randomized studies involving almost 6000 patients were conducted comparing carotid surgery with carotid stenting. In a meta-analysis, no differences were found for the endpoints of death, stroke, and myocardial infarction. Carotid surgery showed a slight superiority for the endpoint of ipsilateral stroke. 

Since 1990, medical treatment has dramatically improved. In addition to antiplatelet drugs and better antihypertensive drugs, we now have much better medications available for treating elevated glucose levels and diabetes, medications for treating lipid metabolism disorders, obesity treatment, and the management of risk factors, like programs for smoking cessation, regular physical activity, and healthy diet. 

As a result, the 5-year risk for stroke has fallen from 11% in the 1990s to 2.5% in 2026. There are also predictors of increased stroke risk in people with asymptomatic carotid stenosis, and these include high-degree stenosis of more than 80%, evidence of microembolism in transcranial Doppler, plaque ulceration in duplex sonography, progressive stenosis of the internal carotid artery, and clinically silent infarct on MRI of the brain. 

Enter CREST-2 at ISC

The purpose of this video is the publication of the CREST-2 study in The New England Journal of Medicine and the presentation of the study at the International Stroke Congress. This was by far the largest and best planned and -conducted study comparing best medical therapy and carotid stenting in 1245 patients, with carotid endarterectomy in 1240 patients. The primary endpoint was stroke or death, and this was 6% for best medical therapy and 2.8% for stenting. This corresponds to a relative risk reduction of 3.2%, which was statistically significant. 

For carotid surgery, the rate of stroke and death was 5.3% vs 3.7%, so the relative risk reduction was 1.6%, and this was statistically not significant. If we calculate numbers needed to treat, these were 31 for stenting compared to best medical therapy, and 63 for carotid surgery compared to best medical therapy. 

The CREST-2 study also showed that carotid stenting is associated with a slightly higher therapeutic benefit compared to best medical treatment. No superiority for cardiac surgery over optimal medical treatment was observed. The low risk for ipsilateral stroke is noteworthy. This risk ranged between 0.4% and 1.7% per year across all four groups of therapy. 

In contrast to earlier studies, the CREST-2 study excluded myocardial infarction as an endpoint, and this makes sense because carotid surgery or carotid stenting usually has no impact on the risk for myocardial infarction.

Caveats and Limitations of CREST-2

Unfortunately, serious bleeding complications were not reported in the study. And these are relevant because after carotid stenting, dual antiplatelet therapy has to be administered at least for a few weeks. 

It is also important to note that there was a rigorous selection of vascular surgeons and interventionalists, and this might not translate into everyday clinical practice because we can expect that probably most people who do not have a high load of procedures have a higher complication rate. 

The periprocedural risk was 1% for stroke. This study very closely monitored the management of risk factors and the treatment of concomitant diseases, and in everyday clinical practice, this might not always be achieved.

When a physician discusses with a patient with asymptomatic carotid stenosis or the family, then they have to point out that the initial risk for stroke and death from the procedure itself is about 1.3%, and this must be weighed against the long-term benefit of stenting, where the risk reduction over 5 years is 3.2%. The presence of risk factors for an increased risk for stroke that I have mentioned before should also be taken into account when deciding for or against surgery or stenting of the internal carotid artery. 

In summary, the CREST-2 study is by far the best planned and -conducted study for the management of asymptomatic carotid stenosis. If one decides to perform a procedure, then it should be carotid stenting and not carotid surgery. (I would never do either unless YOUR DOCTOR COMPLETELY GUARANTEES NO PROBLEMS!

Here is why you do neither of those options!

Asymptomatic Blocked Carotids Don't Need Surgery, Large Trial Shows

In my non-medical opinion, verify the Circle of Willis is complete, then close up the offending artery. I functioned extremely well for 13 years with only three arteries feeding the Circle of Willis)

Dear colleagues, ladies and gentlemen, this was the management of asymptomatic cardiac stenosis and the status of knowledge in 2026. I'm Christoph Diener from the Faculty of Medicine at the University of Duisburg-Essen. Thank you very much for listening and watching. 

Thursday, February 5, 2026

New research shows improving blood flow to the brain in arteries with plaque did not improve cognitive skills

 Why would you even think that? With the Circle of Willis being complete there are four arteries feeding the brain, a miniscule improvement in one artery won't bring more oxygen to the brain. 

Doesn't ANYONE IN STROKE KNOW HOW TO THINK?

Proving once again we have blithering idiots in stroke! I would never do stenting or a carotid endarterectomy because of the possible bad consequences (i.e. stroke).

New research shows improving blood flow to the brain in arteries with plaque did not improve cognitive skills

Improving blood flow to the brain by opening a narrowed neck artery may not improve patients’ cognitive skills, according to a preliminary late-breaking science presentation at the American Stroke Association’s International Stroke Conference 2026

“Whether patients undergo a procedure to remove plaque in the carotid artery, known as a carotid endarterectomy, stenting to insert a flexible tube to hold open the narrowed part of the artery, or a combination of medications and lifestyle guidance without a procedure, there should be no expectation that cognition will improve after the treatment,” said study lead author Ronald M. Lazar, Ph.D., a professor of neurology at the University of Alabama at Birmingham and director of the UAB Evelyn F. McKnight Brain Institute

Carotid artery stenosis is a condition where the major blood vessels in the neck become narrowed, usually because of plaque buildup. Standard treatment focuses on strong medical therapy — such as aspirin to prevent blood clots, medicines to control blood pressure and cholesterol, and lifestyle changes like quitting smoking, being more active, eating a healthy diet and losing weight when needed. When the artery becomes severely narrowed, or more than 70 percent blocked, doctors may also recommend a procedure to reopen it, either through carotid endarterectomy or stenting.

The CREST‑2 Trial (Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis) compared how often strokes occurred in people who were randomly assigned to one of three groups: intensive medical therapy alone, medical therapy plus carotid endarterectomy or medical therapy plus stenting.

Earlier studies have generally shown that people with carotid stenosis tend to do worse on cognitive tests. To examine this more closely, CREST‑2 included a special “cognitive core” component. Participants completed cognitive testing before treatment and then once a year for up to four years. This was the first large randomized trial of carotid stenosis to include cognitive performance as a major outcome.

“The brain needs a steady flow of blood to get oxygen for its cells. When blood vessels can’t deliver enough blood, the brain doesn’t get enough oxygen, and the neurons can’t work properly, which impacts the brain’s ability to function properly. This often leads to changes in cognitive skills like attention, processing speed and decision-making skills,” Lazar said.

In 2021, Lazar and colleagues published results in Stroke, the journal of the American Stroke Association. They found that, before treatment, 786 patients in CREST‑2 with severe but symptom‑free carotid stenosis scored lower on cognitive tests — especially memory — compared with a separate group of people matched for age, sex and cardiovascular risk factors.

“The 2021 analysis indicated that revascularization might improve cognitive function,” said Lazar, who is the principal investigator of the Cognitive Core substudy and an overall co‑investigator for CREST‑2.

However, after an average of 2.8 years of follow‑up, the substudy found no meaningful differences in thinking or memory between people who had a procedure (stenting or surgery) and those who only received intensive medical therapy. “Even among participants with the lowest cognitive function at the start of the study, who were expected to gain the most from these treatments, there were still no differences in cognitive skills among the treatment groups,” Lazar said.

Participants who had a stroke during the study did show cognitive decline, confirming that the cognitive tests were sensitive enough to detect real changes in brain function.

These findings may influence how clinicians talk with patients about the potential benefits of surgery or stenting. 

“Health care professionals can no longer assert that treatment of carotid stenosis will improve cognition. However, worsening cognition over time may be a signal that treatment may need to be reevaluated and possibly adjusted,” Lazar said.

The study could not determine whether reduced blood flow alone explains cognitive decline in people with carotid artery disease. “Some characteristics of a blockage can cause small particles to travel to the brain. These particles may, over time, affect how the brain functions. This is an area we plan to explore in our future research,” Lazar said.

The study had limitations. All cognitive testing was done by phone, which meant researchers could not assess visuo‑spatial skills or the full range of executive functions like complex decision‑making. In addition, only English‑speaking participants were included, which means the results may not apply to people from other language or cultural backgrounds.

At UAB, Lazar holds the Evelyn F. McKnight Endowed Chair for Learning and Memory in Aging.

Tuesday, January 6, 2026

Cognitive Impairment Risk Increases With Carotid Stenosis Severity

My right carotid artery was at 80% blockage at time of stroke and then thankfully fully closed up 3 years later. Remained closed for 10 years and I cognitively functioned quite well with no episodes of fainting or poor executive functioning. Eventually collaterals grew around the blockage. Since my Circle of Willis is complete, I still had 3 fully functioning arteries supplying blood to the brain, obviously enough to keep me highly functioning. I'm glad that my doctors were so incompetent they never found that 80% blockage, otherwise they probably would have insisted I undergo either stenting or endarterectomy, both of which they couldn't guarantee no problems. And I didn't find out about those problems until years later researching for this blog.

Cognitive Impairment Risk Increases With Carotid Stenosis Severity

 Increased severity of carotid stenosis is significantly associated with poorer executive function and slower processing speed, independent of traditional vascular risk factors and history of stroke. Patients with greater carotid stenosis demonstrate significantly worse processing speed and executive function performance compared with those who have less severe disease, according to results of a study published in Alzheimer’s & DementiaAsymptomatic extracranial carotid atherosclerotic disease (aECAD) has been associated with a 22% increased risk for Alzheimer disease, but previous studies evaluating the effect of aECAD on cognitive outcomes have been limited by methodological biases.To better characterize early cognitive changes associated with aECAD, researchers from the University of Arizona examined data from the Carotid and Mind (CAM) clinical study. The researchers evaluated data from the first 182 individuals enrolled in CAM between 2022 and 2024, of whom 167 were included in the final analysis. Participants were aged 50 to 85 years and were recruited from vascular surgery and cardiology clinics. All participants underwent magnetic resonance imaging (MRI), carotid stenosis assessment using North American Symptomatic Carotid Endarterectomy Trial criteria, and comprehensive neurocognitive testing. The researchers defined aECAD as greater than 50% carotid stenosis without a history of stroke or transient ischemic attack in the previous 6 months. This work builds momentum for clinical management changes and future studies with a long-term goal of dementia prevention.
The study population had a mean (SD) age of 72 (7) years, 57% were men, 96% were White, 49% had 13 to 16 years of education, 36% had less than 50% carotid stenosis, and 26% carried the apolipoprotein E (APOE) ε4 allele.

After adjusting for age, sex, race, and ethnicity, increasing carotid stenosis severity was significantly associated with slower processing speed (adjusted b [ab], -0.20; 95% CI, -0.34 to -0.07; P =.004) and poorer executive function (ab, -0.19; 95% CI, -0.33 to -0.05; P =.009).

At the individual test level, greater carotid stenosis was associated with worse performance on the Wechsler Adult Intelligence Scale (ab, -0.26; 95% CI, -0.40 to -0.12; P <.001), Stroop Color-Word Interference (ab, -0.21; 95% CI, -0.35 to -0.07; P =.003), and Trail Making Test part A (ab, -0.21; 95% CI, -0.36 to -0.06; P =.007). Using these 3 tests, a composite Carotid Cognitive Index (CCI) was formulated.

The CCI was also inversely related with phosphorylated tau217 (p-tau217; r, -0.33; P <.001). This relationship was independent of white matter lesion volume (ab, -0.27; P =.006); demographic factors of age, gender, race, ethnicity, and education (ab, -0.24; P =.005); vascular risk factors (ab, -0.22; P =.01); APOE ε4 status (ab, -0.21; P =.01); and vascular disease history (ab, -0.21; P =.02). Higher p-tau217 levels were independently associated with APOE ε4 carriership (b, 0.57; P <.001).

Study limitations include a lack of racial and ethnic diversity.

The study authors concluded, “Although patients with carotid disease are not regularly evaluated clinically for cognitive impairment or dementia, this work builds momentum for clinical management changes and future studies with a long-term goal of dementia prevention.”

Disclosures: One study author declared affiliations with biotech, pharmaceutical, and/or device companies. Please see the original reference for a full list of authors’ disclosures.

Friday, November 21, 2025

Asymptomatic Blocked Carotids Don't Need Surgery, Large Trial Shows

 

Why would you want to do stenting or endarterectomy at all if your doctor won't guarantee no problems?

I still don't understand why you would medically need to stent a carotid artery or do an endarterectomy at all if the Circle of Willis is complete. (Unless the whole point is revenue and profit generation) It would seem to make more sense to just close it up and prevent problems from there.  My right carotid artery was closed for 10 years and I cognitively functioned quite well with no episodes of fainting.

Here is why your doctor needs to GUARANTEE NO complications from stenting!

The latest here:

Asymptomatic Blocked Carotids Don't Need Surgery, Large Trial Shows

Stenting high-grade carotid stenosis did help prevent stroke or death, but experts question worth

Key Takeaways

  • Most carotid-artery stenting or endarterectomy is done for asymptomatic cases.
  • The large CREST-2 randomized trial now shows that endarterectomy holds no stroke and mortality benefit over intensive medical management alone.
  • Stenting did provide a stroke or death prevention benefit over 4 years compared with medical treatment alone but the absolute difference in rates was small and experts suggested reserving this option for symptomatic patients.

For asymptomatic carotid stenosis, stenting helped prevent strokes compared with modern medical treatment whereas endarterectomy did not in the CREST-2 randomized trials.

The primary composite endpoint of any stroke or death at 44 days or ipsilateral ischemic stroke out to 4 years of follow-up occurred in 2.8% of patients randomly assigned to carotid stenting versus 6.0% in those on medical therapy alone (P=0.02), reported James F. Meschia, MD, of the Mayo Clinic in Jacksonville, Florida, and colleagues in the New England Journal of Medicine.

That rate was 3.7% with endarterectomy compared with 5.3% on medical therapy, a difference which didn't meet statistical significance (P=0.24).

"We can conclude that there is no longer a role for routine carotid endarterectomy in persons with asymptomatic stenosis," concluded an accompanying editorial by Martin M. Brown, FRCP, of University College London, and Leo H. Bonati, MD, of Basel University in Switzerland.

Some 75-80% of carotid-artery stenting or endarterectomy recipients in the U.S. are asymptomatic, although management has been controversial.

"Decades ago, surgery clearly helped prevent strokes in many patients," co-author Thomas Brott, MD, also of the Mayo Clinic in Jacksonville, noted in a statement. "But medical therapy has improved so much that we needed to reexamine the balance between benefit and risk for people who have no symptoms."

Along with the previous CREST trial that showed in 2010 that the two procedures had similar short- and longer-term outcomes in symptomatic and asymptomatic individuals at average surgical risk (albeit with more periprocedural strokes in the stenting group), the Second Stent-Protected Angioplasty versus Carotid Endarterectomy (SPACE-2) trial had similar results. The recent but smaller Second European Carotid Surgery Trial (ECST-2) also showed no advantage to revascularization over medical management alone.

But despite statistical significance favoring stenting in CREST-2, the editorialists cautioned against widespread adoption for asymptomatic but high-grade (≥70%) stenosis like that in the trial.

"The benefit from revascularization of asymptomatic carotid stenosis with regard to stroke prevention has become small with improved medical therapy," they wrote, calculating that the event rates meant 95 of every 100 patients would have had an unnecessary procedure over a 4-year period.

Also, the trial reflected a best-case scenario for the procedure, with careful selection of patients and skilled interventionists that would not be available in all vascular centers, Brown and Bonati noted. Medical therapy wasn't perfect either, with only 60-70% of the patients achieving a systolic blood pressure under 130 mm Hg, less than 80% getting LDL cholesterol within the 70 mg/dL target, and only about half of diabetes patients reaching HbA1c goals.

Since two-thirds of the events in patients treated with medical therapy alone were nondisabling strokes that would be expected to lead to good or fair recovery and put them in line for secondary prevention carotid revascularization, the editorialists suggested a pragmatic strategy: "We therefore consider it reasonable to advise patients with asymptomatic carotid stenosis to start intensive medical therapy immediately and to delay revascularization until such time as symptoms develop, which will occur in only a small proportion of patients. Exceptions would then be made for patients who prefer to take the risk of revascularization or who cannot take medical therapy -- in which case, stenting would be the choice for suitable patients at a center with skilled and experienced interventionists."

CREST-2 comprised two parallel trials in patients with at least 70% asymptomatic carotid stenosis seen at 155 centers in five countries. One trial randomly assigned 1,245 adults to receive either intensive medical management alone or with carotid-artery stenting. The other trial randomized 1,240 patients to intensive medical management alone or with endarterectomy.

Serious complications were uncommon with either procedure.

One limitation was the trials' single-blind design in which patients and treating physicians were aware of treatment group assignment; another was that the trial predated the new lower systolic blood pressure guidelines, the advent of PCSK9 inhibitors, and widespread dissemination of new, highly effective diabetes and obesity medication. Transcarotid-artery revascularization, while now in frequent use, wasn't incorporated in the trial.

Importantly, "the difference between stenting and medical management was based on a small number of events," the editorialists noted, such that the primary endpoint was fragile. Only three more events in the stenting group would have tipped the trial to a neutral finding.

Brott suggested that personalized decision making should play a key role, with stenting being more appealing particularly for patients with higher-grade stenosis or plaque that appears unstable or more likely to cause a blockage.

"What we need now are trials focusing on identification of the small proportion of patients with carotid stenosis in whom symptoms develop despite the use of medical therapy," the editorialists wrote, concurring with Meschia's group. "The most promising approach uses magnetic resonance imaging of carotid-artery plaque to identify intraplaque hemorrhage, a strong risk factor for stroke."